Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

Toyoshi Yanagihara, Kunihiro Suzuki, Ayaka Egashira, Naruhiko Ogo, Tatsuma Asoh, Tsukasa Nara, Kensaku Takatsuki, Seiji Yoshizawa, Sy Giin Chong, Naoki Hamada, Takashige Maeyama

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just been approved for treatment of progressive fibrosing ILD, but to date, no reports of RP-ILD treated with nintedanib have been published. This case report may advance discussions regarding the use and timing of nintedanib in treating RP-ILD.

Original languageEnglish
Article number101272
JournalRespiratory Medicine Case Reports
Volume31
DOIs
Publication statusPublished - Jan 2020

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies'. Together they form a unique fingerprint.

Cite this